VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...

"In 2024, Kenmare delivered EBITDA of $157 million, supporting our ability to fund our capital programme and continue to make shareholder distributions. As such, the Board is proposing a full year ...

Behold: These gifts for teens are ones that they'll actually like and want to use. As a parent or guardian of a teen, you’ve ...